AllDocs -> cancers

State-of-the-Art Symposium on Second Mayo Clinic Myeloma February 5-7, 2 0 0 4 The Ritz-Carlton Hotel Amelia Island, Florida Page 2 General Information Course Description This two-day course is designed to bring together experts in a symposium covering state-of-the-art topics in the pathogenesis, disease biology and treatment of myeloma . Course Learning Objectives Upon completion of this course participants will be able to: • Explain myeloma pathogenesis. • Describe the biology of Monoclonal Gammopathy of Unknown Significance (MGUS), Smoldering Myeloma , Myeloma and Asymptomatic Multiple Myeloma . • Identify new targets and translational therapy to advance the therapy and cure of myeloma . • Incorporate new cytogenetic and molecular genetic methods to clinical practice. ...

IBMS Sussex Branch: Multiple Myeloma Dr Graham Meade recently spoke to the Sussex Branch on the topic of multiple myeloma . He explained that the disease was a tumour of plasma cells. The proliferating cells were monoclonal and tended to form multiple foci in the bone marrow. As the cells were monoclonal they all secreted an antibody that was identical in both type and specificity. In 83% of cases an intact antibody was produced. Free light chains only were secreted in 15% of patients. In the remaining 2% there was no evidence of secretion of immunoglobulin or its components. A progressive spectrum of disease was observed. The mildest form was called monoclonal gammopathy of uncertain significance (MGUS). This stage could persist for a number of years and was best left untreated with the patient being monitored for signs of disease progression. An intermediate presentation was smouldering or indolent myeloma ...

September, 2003 This Report on Leukemia, Lymphoma and Multiple Myeloma Contains: • Cancers by Age Group and Gender • Incidence Rates by Gender and Race • Survival Probabilities • Risk Factors • Sources of Additional Information The Ohio Cancer Incidence Surveillance System (OCISS) Blood-related cancers originate in the bone marrow (Leukemia and Multiple Myeloma ) or lymphatic tissue (Non-Hodgkin’s and Hodgkin’s Lymphomas). These cancers involve the uncontrolled growth of cells with similar functions and origins and result from an acquired genetic injury to DNA of a single cell, which becomes malignant (cancerous) and multiplies continuously. The accumulation of malignant cells interferes with the body’s production of healthy blood cells and ability to protect itself against infections. ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORTGROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? DECEMBER NOTES Meeting: Tuesday December 16, 2003 NOTE LOCATION CHANGE FOR DEC. Trudy & Bob Miller 6209 Mendota Ave. Time: 3:30 ? 5:30 PM Middleton, WI 53562 Program: Relaxation, Refreshments, & Hor d’oeuvres More Information: Chuck Koval &n...

[2558] Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma : A UK Myeloma Forum Phase 2 Study. Session Type: Poster Session 729-II Sylvia Feyler, Graham Jackson, Andy Rawstron, Yasser M. EL-Sherbiny, John A. Snowden, Roderick J. Johnson Haematology, St James s University Hospital, Leeds, Yorkshire, United Kingdom; Haematology, Royal Victoria Hospital, Newcastle Upon Tyne, United Kingdom; Haematological Malignancy Diagnostic Service, Leeds General Infirmary, Leeds, Yorkshire, United Kingdom; Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, Yorkshire, United Kingdom Thalidomide has an established role in the therapy of myeloma but available data refers mainly to induction, re-induction or consolidation treatments, with almost no information on its potential use in maintenance. High dose melphalan-based autografting produces good disease control and extends survival. ...

[2553] 10-Year Survival in Myeloma : Have the Results Improved in the Last Decade? Session Type: Poster Session 724-II Raymond Powles, B. Sirohi, S. Singhal, J. Treleaven, S. Kulkarni, C. Horton, C. Dearden, J. Mehta Myeloma unit, Royal Marsden Hospital, Sutton, Surrey, United Kingdom We have previously shown that patients with myeloma who survive longer than 10 y in first complete remission (CR) appear to be on a plateau of survival in which life span and quality of life are normal (Powles et al, Blood 2000: 96;2215a). Thus, focusing on 10-y survival data and measures to improve it may be a crucial end-point for long-term quality of life for myeloma patients. We have studied 167 new patients (median age 52 y, 30-68; 63F; 60% IgG; 81% stage III) with myeloma who were planned to receive infusional chemotherapy plus an autograft (70% received it) with minimum follow-up of 10-y (all diagnosed ...

[659] Molecular Profiles of Sensitivity or Resistance of Multiple Myeloma (MM) Cells to Conventional and Novel Anti- Myeloma Agents: Clinical Implications for Rationale Design of Strategies To Overcome Drug-Resistance in MM. Session Type: Oral Session Constantine S. Mitsiades, Nicholas Mitsiades, Ciaran J. McMullan, Vassiliki Poulaki, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Marie Joseph, Towia A. Libermann, Kenneth C. Anderson Jerome Lipper Multiple Myeloma Center, Dep. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Med. School, Boston, MA, USA; Genomics Center, Harvard Institutes of Medicine, Boston, MA, USA Despite the addition of thalidomide (Thal) (and its immunomodulatory derivatives) or the proteasome inhibitor bortezomib (PS-341) to the therapeutic armamentarium against multiple myeloma (MM), none of the currently available drugs, used either as single agents ...

[3479] t(4;14) in Myeloma Patients Receiving Autologous Stem Cell Transplant Is Associated with Inferior Clinical Outcome. Session Type: Poster Session 699-III Hong Chang, Stephen Sloan, Dan Li, Lihua Zhuang, Qi-Long Yi, Kathy Chun, Keith Stewart Dept.of Lab Hematology; Dept.of Medical Oncology and Hematology; Dept.of Pathology, Princess Margaret Hospital, Toronto, ON, Canada Multiple myeloma (MM) is characterized by a low proliferative index and associated with translocations involving the immunoglobulin heavy chain locus on chromosome 14q32 and various partner genes. The most common IgH translocations are the t(11;14) and t(4;14). We investigated the frequency and prognostic relevance of the t(11;14) and t(4;14) in a series of 120 patients with multiple myeloma who received intensive chemotherapy (melphalan 200mg/m 2 ) followed by autologous stem cell transplant at our institution. ...

[135] Comparable Survival in Multiple Myeloma (MM) with High Dose Therapy (HDT) Employing MEL 140 mg/m 2 + TBI 12 Gy Autotransplants Versus Standard Dose Therapy with VBMCP and No Benefit from Interferon (IFN) Maintenance: Results of Intergroup Trial S9321. Session Type: Oral Session Bart Barlogie, Robert Kyle, Kenneth Anderson, Phil Greipp, Hillard Lazarus, Joth Jacobson, Erik Rasmussen, Jeana Cromer, John Crowley Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Mayo Clinic, Rochester, MN, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Ireland Cancer Center, University Hospital of Cleveland, Cleveland, OH, USA; Cancer Research and Biostatistics, Seattle, WA, USA; on behalf of SWOG, CALGB, ECOG ECOG, CALGB and SWOG enrolled 899 patients with newly diagnosed MM to receive VAD induction x 4 cycles (n=805), ...

[511] The Translocation t(4;14) in Multiple Myeloma (MM): Frequency and Prognostic Relevance in Previously Untreated Patients Receiving Either Single or Double Autotransplants. Session Type: Oral Session Carolina Terragna, Michele Cavo, Simona Soverini, Claudia Cellini, Nicoletta Testoni, Antonello De Vivo, Marilina Amabile, Barbara Giannini, Emanuela Ottaviani, Tiziana Grafone, Angela Poerio, Michele Bianchini, Elena Zamagni, Patrizia Tosi, Delia Cangini, Paola Tacchetti, Sante Tura, Michele Baccarani, Giovanni Martinelli (Intr. by Giovanni Martinelli) Institute of Hematology and Medical Oncology L & A Ser gnoli , University of Bologna, Bologna, Italy In patients with MM a number of recurrent translocations involving chromosome 14 at band q32 have been recently identified, the most common being the t(11;14) and the t(4;14). Both these chromosomal abnormalities may help to identify patients at ...

[1639] Phase I Study of the Proteasome Inhibitor Bortezomib in Combination with Pegylated Liposomal Doxorubicin in Patients with Refractory Hematologic Malignancies. Session Type: Poster Session 751-I Robert Z. Orlowski, Peter M. Voorhees, Reynaldo A. Garcia, Melissa D. Hall, Mary J. Lehman, Anandhi Johri, Elizabeth Humes, Julian Adams, Dixie L. Esseltine, Don A. Gabriel, Thomas C. Shea, Hendrik W. Van Deventer, Beverly S. Mitchell, Claire Dees Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA Introduction: The proteasome, a multicatalytic proteinase complex involved in intracellular protein degradation, is a novel target for therapy of hematologic malignancies. In addition, proteasome inhibitors may block survival pathways such as NF- B that are activated by anthracyclines, suggesting that such combinations ...

MULTIPLE MYELOMA AND DIESEL AND OTHER OCCUPATIONAL EXPOSURES IN SWEDISH CONSTRUCTION WORKERS Won Jin L EE 1 *, Dalsu B ARIS 1 , Bengt J ¨ ARVHOLM 2 , Debra T. S ILVERMAN 1 , Ingvar A. B ERGDAHL 2 and Aaron B LAIR 1 1 Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA 2 Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden We examined the relationships between occupational ex- posures and the risk of multiple myeloma among male con- struction workers in Sweden. A total of 446 myeloma sub- jects were identified among 365,424 male workers followed from 1971 to 1999. Occupational ...

myeloma Multiple Myeloma Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin ( M protein ) Incidence: 3 - 9 cases per 100000 population / year more frequent in elderly modest male predominance Multiple Myeloma Clinical forms: multiple myeloma solitary plasmacytoma plasma cell leukemia M protein: ...

Cell biological roles of IL-10 in myeloma cells Takemi Otsuki , Kenichiro Yata , Haruko Sakaguchi , Hideho Wada , Takashi Sugihara and Ayako Ueki IL-10,along with interleukin (IL)-6,are considered two of the most important cytokines that regulate the proliferation and cellular characteristics of myeloma cells. It remains unclear from the clinical data how levels of IL-10 in serum at various stages of myeloma are related to clinical manifestations of this disease. Several studies have reported that IL-10 affects myeloma cells by stimulating secondary signals for cell proliferation through oncostatin M (OSM)and IL-11. In experiments using human myeloma cell lines that were established in our laboratory,IL-10 seemed to be expressed in half of myelomas simulta- neously with OSM, and was correlated with c-maf, a transcription factor that has been known to be overexpressed in myelomas with t (14; 16)(q32; ...

Cytogenetic Study of 48 Patients with Multiple Myeloma and Related Disorders Takashi Nimura,Ikuo Miura,Yoshimi Kobayashi,Tomoko Yoshioka, Masaaki Kume,Naoto Takahashi,Makoto Hirokawa, Akira B. Miura and Ken-ichi Sawada We studied 48 patients with multiple myeloma and its related disorders (plasma cell dyscrasias: PCD). Clonal changes were observed in 19 patients (39.6%), which included 9 untreated and 10 treated patients. Chromosomal gains of 3, 11 and loss of 13 were the most frequent numerical chromosome aberrations. Chromosome 13 was lost at an early stage and 17p (p53) abnormality appeared in an advanced stage of the disease. The most common additional region was 1q which contained a locus of the IL-6 receptor gene instead of 7p,the locus of the IL-6 gene. The break points were clustered at 1p13, 6q21,7p11.2 14q32,17p11 and 19p13.3,which were the loci of protooncogenes,tumor suppresser genes or ...

C A S E R E P O R T * Medical Specialist ** Sr. Consultant & Head Department of Medicine ESI Hospital, Basaidarapur, New Delhi-110 015. JIACM 2002; 3(1): 93-5 Multiple Myeloma with Extra-Medullary Dissemination in the Lung Ramnik K Duggal*, KA Ramachandran** Multiple myeloma (MM) represents malignant disorder of plasma cells. This disorder presents primarily in the elderly, with organ dysfunctions and symptoms such as bone pains, renal dysfunction, anaemia, susceptibility to infections, hypercalcaemia, hyperviscosity, and neurological manifestations. Despite widespread distribution of plasma cells in the body, the tumour extension is primarily within the bone and bone-marrow 1 . We present here a case of multiple myeloma , in whom the malignant plasma cells had disseminated to the lung parenchyma. Case report ...

Last revised 11/7/2003 UM Cancer Center Patient Education Document #0046 Nov03 Ed. Online version at: http://www.cancer.med.umich.edu/learn/pwadultsarcoma.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Multiple Myeloma The purpose of this information guide is to help patients newly diagnosed with Multiple Myeloma find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center of the University of Michigan Comprehensive Cancer Center, in room B1-361. Pamphlets Available free in the Patient Education Resource Center on level B-1 The Leukemia & Lymphoma Society. Myeloma Full-text available ...

myeloma Multiple Myeloma and Other Plasma Cell Neoplasms General Information Cellular Classification Stage Information Multiple myeloma Stage I multiple myeloma Stage II multiple myeloma Stage III multiple myeloma Isolated plasmacytoma of bone Extramedullary plasmacytoma Macroglobulinemia Monoclonal gammopathy of undetermined significance Treatment Option Overview Multiple Myeloma Conventional chemotherapy treatment options High-dose chemotherapy options for symptomatic myeloma Isolated Plasmacytoma of Bone Extramedullary Plasmacytoma Waldenström's Macroglobulinemia (Lymphoplasmacytic Lymphoma) Monoclonal Gammopathy of Undetermined Significance Refractory Plasma Cell Neoplasm Changes to This Summary (02/20/2003) ...

Leukemia (1998) 12 , 1295–1302 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu Specific detection of myeloma plasma cells using anti-idiotypic single chain antibody fragments selected from a phage display library PMW Willems 1 , RMA Hoet 2 , ELPG Huys 1 , JMH Raats 2 , EJBM Mensink 1 and RAP Raymakers 1 1 Department of Internal Medicine, Division of Hematology, University Hospital Nijmegen; and 2 Department of Biochemistry, Catholic University Nijmegen, The Netherlands Bone marrow plasma cells constitute the bulk of malignant cells in multiple myeloma patients. B-lymphocytes having immunoglobulin heavy chain gene rearrangements identical to those of the malignant clone (clonally related B-lymphocytes) ...

Version 1.1 / February 2003 MYELOMA IX TRIAL PROTOCOL SUMMARY INDICATION Multiple myeloma requiring treatment (International Myeloma Working Group definition) in patients of all age groups. OBJECTIVES For ‘younger/fitter’ patients considered appropriate for high-dose chemotherapy Primary • To compare two induction regimens, CVAD (infusional) v C-Thal-Dex (CTD) (oral) • To compare two bisphosphonates, namely sodium clodronate (2 nd generation) v zoledronic acid (3 rd generation) • To assess the value of giving low-dose thalidomide in maintenance (versus no treatment) • To assess low-intensity conditioning (LIC) (non-ablative) allogeneic stem cell transplantation (‘mini- allograft’) following standard high-dose melphalan with autograft in patients with donors available. For ‘older/less ...

myeloma WISCONSIN MULTIPLE MYELOMA SUPPORTGROUP ?Providing an opportunity for multiple myeloma patients and their loved ones to exchange information, for mutual support, comfort, and friendship.? NOVEMBER NOTES Meeting: Tuesday, November 18, 2003 UW Health ? West Clinic Time: 3:30 ? 5:30 PM 451 Junction Road Madison, WI 53717-2656 Program: Cindy Starks, Nutrition Educator Natural Ovens Bakers More Information: Chuck Koval &nbs...

Page 1 of 4 of Instrument No.55 of 2003 Instrument No.55 of 2003 Revocation and Determination of Statement of Principles concerning MYELOMA Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.72 of 1999; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about myeloma and death from myeloma . (b) For the purposes of this Statement of Principles, “ myeloma ” means a malignant disease of plasma cells, in which a single line of plasma cells accumulates and produces a monoclonal immunoglobulin. This definition includes plasma cell leukaemia, multiple myeloma and ...

myeloma The UK Myeloma Forum Summer Meeting 25th June 2003 76 Portland Place London W1B 1NT Registration Form In order to support this meeting it will be necessary to charge a modest registration fee. The fee will be £40 for Consultants and tenured Scientists and £20 for all others. This will contribute to the costs of the meeting and include all refreshments. Travel Directions will be sent with acknowledgement of your registration. Please ensure that your fax number is legible as these may be faxed. Name . Job Title . Address . . . Tel No . Fax No . Email . Payment enclosed: Consultant Grade post £40 &n...

Page 1 of 3 of Instrument No.56 of 2003 Instrument No.56 of 2003 Revocation and Determination of Statement of Principles concerning MYELOMA Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.73 of 1999; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about myeloma and death from myeloma . (b) For the purposes of this Statement of Principles, “ myeloma ” means a malignant disease of plasma cells, in which a single line of plasma cells accumulates and produces a monoclonal immunoglobulin. This definition includes plasma cell leukaemia, multiple myeloma and ...

Multiple myeloma Design: The Almond Consultancy ,Edinburgh, UK. Bone marrow cancer an introduction UK Myeloma Awareness Week 21-28 June Published by the International Myeloma Foundation (UK) May 2001 Page 2 Contents What is Myeloma ? 1 What causes Myeloma ? 1 Signs and Symptoms 2 Diagnosis 3 Treatment 4 Chemotherapy 4 Radiotherapy 5 Transplantation 5 Maintenance Therapy 6 Aim of Treatment and Prognosis 7 How to contact the International Myeloma Foundation (UK) 8 What is Myeloma ? Multiple Myeloma is a relatively rare cancer of the plasma cells. Plasma cells are found in the bone marrow and are responsible for protecting the body against viruses and infections. In Myeloma , a single defective ...

Multiple myeloma A Concise Review of the Disease and Treatment Options Prepared by Brian G. M. Durie, MD Page 2 Contents p 1 Introduction p 2 What is Myeloma ? p 6 History p 11 Epidemiology and Pathophysiology p 14 Clinical Symptoms p 15 Staging and Prognostic Factors p 18 Definition of Clinical Response p 19 Treatment p 36 References Mission Statement Dedicated to improving the quality of life of Myeloma patients while working towards prevention and a cure. This is one of a range of publications covering many aspects of living with Multiple Myeloma . Please contact the IMF (UK) for more details. This is an overview of the history of myeloma , a discussion of pathophysiology, clinical features plus treatment options. It is written for physicians ...

Published by the International Myeloma Foundation (UK) May 2001 9 Gayfield Square Edinburgh EH1 3NT Tel: +44 (0) 131 557 3332 Helpline: 0800 980 3332 (UK only) Fax: +44 (0) 131 556 9720 E-mail: TheIMF@ myeloma .org.uk Website: www. myeloma .org.uk Charity Registration Number: SC 026116 Company Number: 190563 UK Myeloma Awareness Week 21-28 June Multiple myeloma The basics Design: The Almond Consultancy ,Edinburgh, UK. Page 2 Contents p 1 Introduction p 2 What causes Myeloma ? p 3 What is Myeloma ? p 6 The most common features of Multiple Myeloma p 7 Initial Diagnosis p 8 Investigations to confirm a diagnosis p 10 What’s NOT Myeloma ? p 12 Staging and Prognostic Factors p 15 Treatment p 16 Direct approaches ...

Myeloma updated 1st edition 1998 Robert A. Kyle MANUAL Multiples Myelom © 2002 by Tumorzentrum München und W. Zuckschwerdt Verlag München VII the size of the M-protein and the number of bone marrow plasma cells are helpful in diagnosis, we find that the plasma cell labelling index and the presence of circulating peripheral blood plasma cells are also useful. Virtually all patients with an elevated plasma cell labelling index or circulating plasma cells in the peripheral blood have active multiple myeloma . The physician must realise that the presence of a normal plasma cell label- ling index or absence of circulating plasma cells does not exclude the possibility of active multiple myeloma . If the patient is younger than 65 or 70 years, the physician should discuss the possibility of auto- logous peripheral blood stem cell transplanta- tion. ...

Editorial C a n c e r C o n t r o l September/October 2003, Vol. 10, No.5 Cancer Control 357 Multiple myeloma is a malig- nancy characterized by the prolif- eration of clonal plasma cells pref- erentially in the bone marrow. The second most common hematologic malignancy, this diagnosis is newly made in 35,000 persons yearly worldwide. Over 40 years ago, Bergsagel and others showed that a combina- tion of melphalan and prednisone was an effective chemotherapy reg- imen in myeloma , inducing responses in over 50% of newly diagnosed patients. For decades, this simple combination remained the standard treatment for myelo- ma since other chemotherapy regi- mens failed to show improved sur- vival when compared to it. It was not until 1995, when high-dose chemotherapy ...

Thalidomide and Its Derivatives: New Promise for Multiple Myeloma Donna Weber, MD Background: The combination of melphalan and prednisone has been accepted as standard treatment for multiple myeloma (MM) because most studies demonstrate only minimal survival benefit of combination chemotherapy regimens when compared with melphalan and prednisone. Despite modest gains with more intensive myeloablative regimens for certain subgroups, myeloma remains incurable. In 1999, investigators at the University of Arkansas reported the promising results of a phase II study of thalidomide in patients with resistant MM. Since then various trials of thalidomide alone, and in combination, have been tested in patients with resistant, and more recently, untreated MM. In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have recently been reported. ...